Literature DB >> 22080441

Pubertal androgenization and gonadal histology in two 46,XY adolescents with NR5A1 mutations and predominantly female phenotype at birth.

M Cools1, P Hoebeke, K P Wolffenbuttel, H Stoop, R Hersmus, M Barbaro, A Wedell, H Brüggenwirth, L H J Looijenga, S L S Drop.   

Abstract

OBJECTIVE: Most patients with NR5A1 (SF-1) mutations and poor virilization at birth are sex-assigned female and receive early gonadectomy. Although studies in pituitary-specific Sf-1 knockout mice suggest hypogonadotropic hypogonadism, little is known about endocrine function at puberty and on germ cell tumor risk in patients with SF-1 mutations. This study reports on the natural course during puberty and on gonadal histology in two adolescents with SF-1 mutations and predominantly female phenotype at birth. DESIGN AND METHODS: Clinical and hormonal data and histopathological studies are reported in one male and one female adolescent with, respectively, a nonsense mutation (c.9T>A, p.Tyr3X) and a deletion of the first two coding exons (NCBI36/hg18 Chr9:g.(126306276-126307705)_(126303229-126302828)del) of NR5A1, both predicted to fully disrupt gene function.
RESULTS: LH and testosterone concentrations were in the normal male range, virilization was disproportionate to the neonatal phenotype. In the girl, gonadectomy at 13 years revealed incomplete spermatogenesis and bilateral precursor lesions of testicular carcinoma in situ. In the boy, at the age of 12, numerous germ cells without signs of malignancy were present in bilateral testicular biopsy specimen.
CONCLUSIONS: In SF-1 mutations, the neonatal phenotype poorly predicts virilization at puberty. Even in poorly virilized cases at birth, male gender assignment may allow spontaneous puberty without signs of hypogonadotropic hypogonadism, and possibly fertility. Patients with SF-1 mutations are at increased risk for malignant germ cell tumors. In case of preserved gonads, early orchidopexy and germ cell tumor screening is warranted. The finding of premalignant and/or malignant changes should prompt gonadectomy or possibly irradiation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22080441     DOI: 10.1530/EJE-11-0392

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  15 in total

Review 1.  Management of disorders of sex development.

Authors:  Olaf Hiort; Wiebke Birnbaum; Louise Marshall; Lutz Wünsch; Ralf Werner; Tatjana Schröder; Ulla Döhnert; Paul-Martin Holterhus
Journal:  Nat Rev Endocrinol       Date:  2014-07-15       Impact factor: 43.330

2.  A non-surgical approach to 46,XY differences in sex development through hormonal suppression at puberty: a single-center case series study.

Authors:  Katie L Canalichio; Margarett Shnorhavorian; Anne-Marie Amies Oelschlager; Linda Ramsdell; Christina Fisher; Margaret P Adam; Patricia Y Fechner
Journal:  Endocrine       Date:  2020-07-08       Impact factor: 3.633

3.  Fluidity models in ancient Greece and current practices of sex assignment.

Authors:  Min-Jye Chen; Bonnie McCann-Crosby; Sheila Gunn; Paraskevi Georgiadis; Frank Placencia; David Mann; Marni Axelrad; L P Karaviti; Laurence B McCullough
Journal:  Semin Perinatol       Date:  2017-05-03       Impact factor: 3.300

Review 4.  Steroidogenic factor-1 and human disease.

Authors:  Ranna El-Khairi; John C Achermann
Journal:  Semin Reprod Med       Date:  2012-10-08       Impact factor: 1.303

5.  Steroidogenic factor 1 differentially regulates fetal and adult leydig cell development in male mice.

Authors:  Tatiana Karpova; Kumarasamy Ravichandiran; Lovella Insisienmay; Daren Rice; Valentine Agbor; Leslie L Heckert
Journal:  Biol Reprod       Date:  2015-08-12       Impact factor: 4.285

Review 6.  Endocrine Management of Ovotesticular DSD, an Index Case and Review of the Literature.

Authors:  Marissa J Kilberg; Michelle McLoughlin; Louisa C Pyle; Maria G Vogiatzi
Journal:  Pediatr Endocrinol Rev       Date:  2019-12       Impact factor: 1.218

Review 7.  DAX-1 (NR0B1) and steroidogenic factor-1 (SF-1, NR5A1) in human disease.

Authors:  Jenifer P Suntharalingham; Federica Buonocore; Andrew J Duncan; John C Achermann
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2015-07-14       Impact factor: 4.690

8.  A novel NR5A1 variant in an infant with elevated testosterone from an Australasian cohort of 46,XY patients with disorders of sex development.

Authors:  Joyce Y Wu; Ivan N McGown; Lin Lin; John C Achermann; Mark Harris; David M Cowley; Salim Aftimos; Kristen A Neville; Catherine S Choong; Andrew M Cotterill
Journal:  Clin Endocrinol (Oxf)       Date:  2013-04       Impact factor: 3.478

9.  State of the art review in gonadal dysgenesis: challenges in diagnosis and management.

Authors:  Bonnie McCann-Crosby; Roshanak Mansouri; Jennifer E Dietrich; Laurence B McCullough; V Reid Sutton; Elise G Austin; Bruce Schlomer; David R Roth; Lefkothea Karaviti; Sheila Gunn; M John Hicks; Charles G Macias
Journal:  Int J Pediatr Endocrinol       Date:  2014-04-14

10.  Functional characterization of novel NR5A1 variants reveals multiple complex roles in disorders of sex development.

Authors:  Gorjana Robevska; Jocelyn A van den Bergen; Thomas Ohnesorg; Stefanie Eggers; Chloe Hanna; Remko Hersmus; Elizabeth M Thompson; Anne Baxendale; Charles F Verge; Antony R Lafferty; Nanis S Marzuki; Ardy Santosa; Nurin A Listyasari; Stefan Riedl; Garry Warne; Leendert Looijenga; Sultana Faradz; Katie L Ayers; Andrew H Sinclair
Journal:  Hum Mutat       Date:  2017-11-02       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.